SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating... | May 3, 2023

Related Keywords

United States ,American ,Saqib Islam ,Samantha Hilson Sandler ,Trademark Office ,Springworks Therapeutics Inc ,Development Rd Expenses ,European Medicines Agency ,American Association For Cancer Research Annual Meeting ,Linkedin ,Drug Administration ,Nasdaq ,American Association For Cancer Research ,Desmoid Tumors Accepted ,Granted Priority Review ,Date Set ,Desmoid Tumors Published ,New England Journal ,Encouraging Clinical Data ,Tumor Programs Presented ,American Association ,Cancer Research Annual Meeting ,Works Therapeutics ,New Drug Application ,Priority Review ,Chief Executive Officer ,Business Highlights ,Springwork New Drug Application ,Prescription Drug User Fee Act ,Marketing Authorization Application ,Maturation Antigen ,Cancer Research ,Annual Meeting ,Springworks Sponsored Phase ,Investigational New Drug Application ,United States Patent ,Orange Book Listable ,Loss Attributable ,Common Stockholders ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Consolidated Statements ,Springworks Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Fda ,Or ,Nirogacestat ,N ,Adults ,Ith ,Esmoid ,Rumors ,Accepted ,Y ,The ,End ,Granted ,Priority ,Pdufa ,Action ,Gate ,Pet ,August ,023 ,Hase , ,Refi ,Rial Swtx Us85205l1070 ,